SSR 69071

structure in first source

Also Known As:

2-(9-(2-piperidinoethoxy)-4-oxo-4H-pyrido(1,2-a)pyrimidin-2-yloxymethyl)-4-(1-methylethyl)-6-methoxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide; SSR-69071; SSR69071

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - SSR 69071: 4
  - Cyclic S-Oxides
    - SSR 69071: 4
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - SSR 69071: 4
- Heterocyclic Oxides
  - Cyclic S-Oxides
    - SSR 69071: 4

Experts

1.	Kapui, Zoltan: 2 articles (05/2003 - 02/2003)
2.	Mikus, Endre: 2 articles (05/2003 - 04/2003)
3.	Ariki, Shimpei: 1 article (10/2021)
4.	Chalalai, Thanyakorn: 1 article (10/2021)
5.	Dewayani, Astri: 1 article (10/2021)
6.	Fukuda, Chiaki: 1 article (10/2021)
7.	Hidano, Shinya: 1 article (10/2021)
8.	Ito, Kanako: 1 article (10/2021)
9.	Kamiyama, Naganori: 1 article (10/2021)
10.	Kayama, Hisako: 1 article (10/2021)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 04/01/2003 - "SSR69071 2-[(4-isopropyl-6-methoxy-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)methoxy]-9-(2-piperidin-1-ylethoxy)-4H-pyrido[1,2-a]pyrimidin-4-one was selected as a novel orally active HLE inhibitor for treatment of chronic obstructive pulmonary diseases, asthma, emphysema, cystic fibrosis and several inflammatory diseases (WO 01/44245 A1) (J. "
2.	Reperfusion Injury 02/07/2003 - "SSR69071, an elastase inhibitor, reduces myocardial infarct size following ischemia-reperfusion injury."
3.	Myocardial Infarction 02/07/2003 - "SSR69071, an elastase inhibitor, reduces myocardial infarct size following ischemia-reperfusion injury."
4.	Ischemia 02/07/2003 - "We evaluated the effects of 2-(9-(2-piperidinoethoxy)-4-oxo-4H-pyridol[1,2-a]pyrimidin-2-yloxymethyl)-4-(1-methyethyl)-6-methoxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide hemihydrate (SSR69071), a novel, potent and selective inhibitor of neutrophil elastase, on infarct size in anaesthetized rabbits subjected to coronary artery occlusion for 30 min followed by reperfusion for 120 min. SSR69071 (3 mg/kg i.v.) reduced cardiac infarct size when administered before ischemia (-39%, P<0.05) or just prior to reperfusion (-37%, P<0.05). "
5.	Infarction (Infarctions) 02/07/2003 - "Subsequent experiments using the latter administration protocol confirmed the ability of SSR69071 (1 and 3 mg/kg i.v.) to reduce infarct size. " 02/07/2003 - "We evaluated the effects of 2-(9-(2-piperidinoethoxy)-4-oxo-4H-pyridol[1,2-a]pyrimidin-2-yloxymethyl)-4-(1-methyethyl)-6-methoxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide hemihydrate (SSR69071), a novel, potent and selective inhibitor of neutrophil elastase, on infarct size in anaesthetized rabbits subjected to coronary artery occlusion for 30 min followed by reperfusion for 120 min. SSR69071 (3 mg/kg i.v.) reduced cardiac infarct size when administered before ischemia (-39%, P<0.05) or just prior to reperfusion (-37%, P<0.05). "

Related Drugs and Biologics

1.	Leukocyte Elastase (Neutrophil Elastase)
2.	Protease Inhibitors (Protease Inhibitor)
3.	Pancreatic Elastase (Elastase)
4.	Carrageenan